Development of the new therapeutic antibodies for mesothelioma

2012 Fiscal Year Final Research Report

• Project/Area Number: 22501026
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Tumor immunology
• Research Institution: Juntendo University
• Principal Investigator: ABE Masaaki 順天堂大学, 医学部, 研究技師 (30398656)
• Project Period (FY): 2010 – 2012
• Keywords: 中皮腫 / 抗体療法 / ERC/Mesothelin / ADCC

Research Abstract

We previously developed anti-human membranous C-ERC/Mesothelin monoclonal antibody 22A31. In this study, we proved 22A31 to have anti-proliferative activity for human mesothelioma cell lines transplanted subcutaneously or intraperitonealy in mice. 22A31 was injected to mice via intratumoral or intraperitoneal routes, and it showed the inhibitory effect for the proliferation of mesothelioma cells in all experiments. Serum concentration of the secretory N-ERC/Mesothelin reflected the extent of the tumor-proliferation, and seemed to be significant in the prediction of the effect of treatment.

Research Products

• [Journal Article] NP-1250, an ABCG2 inhibitor, induces apoptotic cell death in breast carcinoma MCF7/mitoxantrone-resistant cells via a caspase-independent pathway (2013)
  • Author(s): Ito M., Kajino K., Abe M., Fujimura T., Mineki R., Ikegami T., Ishikawa T. and Hino O
  • Journal Title: Int. J. Oncol Rep Volume: 29(4) Pages: 1492-1500
  • DOI: DOI:10.3892
  • Peer Reviewed
• [Journal Article] LRR4 and UPK3B are markers of primary mesothelial cells (2011)
  • Author(s): Kanamori-Katayama M., Kaiho A., Ishizu Y., Okamura-Oho Y., Hino O., Abe M., Kishimoto T., Sekihara H., Nakamura Y., Suzuki H., Forrest A.R.R. and Hayashizaki Y.
  • Journal Title: PLoS One Volume: 6 Pages: e25391-25399
  • DOI: DOI:10.1371
  • Peer Reviewed